Boston Scientific Corporation (BSX)
| Market Cap | 64.78B -55.3% |
| Revenue (ttm) | 21.00B +13.5% |
| Net Income | 3.67B +46.7% |
| EPS | 2.47 +46.9% |
| Shares Out | 1.45B |
| PE Ratio | 17.71 |
| Forward PE | 13.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,705,516 |
| Open | 44.70 |
| Previous Close | 43.72 |
| Day's Range | 44.04 - 44.85 |
| 52-Week Range | 42.20 - 105.65 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 62.00 (+38.7%) |
| Earnings Date | Oct 28, 2026 |
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatogra... [Read more]
Financial Performance
In 2025, Boston Scientific's revenue was $20.07 billion, an increase of 19.87% compared to the previous year's $16.75 billion. Earnings were $2.90 billion, an increase of 56.40%.
Financial StatementsAnalyst Summary
According to 31 analysts, the average rating for BSX stock is "Buy." The 12-month stock price target is $62.0, which is an increase of 38.70% from the latest price.
News
Boston Scientific price target lowered to $65 from $85 at Oppenheimer
Oppenheimer analyst Suraj Kalia lowered the firm’s price target on Boston Scientific (BSX) to $65 from $85 and keeps an Outperform rating on the shares ahead of quarterly results. The…
Citi downgrades Boston Scientific to Neutral on uncertain recovery
Citi downgraded Boston Scientific (BSX) to Neutral from Buy with a price target of $50, down from $57. The company faces a “more mature” U.S. pulsed field ablation market with…
Boston Scientific downgraded to Neutral from Buy at Citi
Citi downgraded Boston Scientific (BSX) to Neutral from Buy with a $50 price target
Boston Scientific Restores Key Operations After Cyberattack
The company said products are moving through its distribution network at or above normal levels as the Marlborough, Mass., company works to fulfill customer orders, reduce backlogs and accelerate the ...
Boston Scientific Transcript: Wells Fargo 21st Annual Healthcare Conference
Operations have fully recovered from a global cyber attack, but financial guidance for Q3 and the full year will not be met. WATCHMAN faces market headwinds and new competition, while EP growth moderates amid strong product launches planned for 2027. The Penumbra acquisition and new platforms in cardiovascular and urology are expected to drive future growth.
Boston Scientific price target lowered to $57 from $61 at Citi
Citi lowered the firm’s price target on Boston Scientific (BSX) to $57 from $61 and keeps a Buy rating on the shares. The firm reduced estimates following the company’s update…
Boston Scientific price target lowered to $56 from $60 at BTIG
BTIG analyst Marie Thibault lowered the firm’s price target on Boston Scientific (BSX) to $56 from $60 and keeps a Buy rating on the shares after the company announced that…
Boston Scientific put volume heavy and directionally bearish
Bearish flow noted in Boston Scientific (BSX) with 14,699 puts trading, or 4x expected. Most active are Oct-26 40 puts and 9/11 weekly 46 puts, with total volume in those…
Boston Scientific Stock (BSX) Slides as Cyberattack Set to Batter Full-Year Profits
Shares in medical technology group Boston Scientific ($BSX) slumped nearly 3% in pre-market trading after it said that last month’s cyberattack on its business would have a material impact on…
Boston Scientific ‘Unlikely to Meet' Earnings Guidance After Cyberattack. Stock Falls.
Boston Scientific stock falls as the medical device maker says a recent cyberattack may make it hard to hit quarterly and full-year guidance targets.
Boston Scientific Won't Meet Guidance Due to Cyberattack
Boston Scientific said it likely won't meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket ...
Boston Scientific says cyberattack likely to hurt 2026 sales, profit
Boston Scientific said on Tuesday a cybersecurity incident that disrupted manufacturing and order shipments globally is likely to have a material impact on its third-quarter and full-year 2026 ...
Boston Scientific says ‘unlikely’ to meet net sales, adjusted EPS guidance
In a regulatory filing, Boston Scientific (BSX) said that on August 25, the company identified a cybersecurity incident that affected certain of its information technology systems and resulted in a…
Boston Scientific says ‘unlikely’ to meet Q3, FY26 guidance ranges
06:24 EDT Boston Scientific (BSX) says ‘unlikely’ to meet Q3, FY26 guidance ranges
TD says Boston Scientific shipping update ‘big step forward’
TD Cowen highlights that Boston Scientific (BSX) yesterday said it has begun restoring shipping capabilities for the majority of its products at its major distribution centers. TD confirmed the capabi...
Boston Scientific Stock Slides After Cyberattack Caused ‘Global Disruption'
Boston Scientific's stock is sliding in the wake of a major cyberattack, adding to its recent woes.
Boston Scientific Stock Price Drops After Cyberattack Triggers Global Outage
The medical-device maker said order processing and shipping have been disrupted.
Medical device maker Boston Scientific says a cyberattack is causing a ‘global disruption' to its operations
A cyberattack on U.S. medical device maker Boston Scientific is causing an ongoing “global disruption” to its operations, according to a federal regulatory filing on Wednesday, the latest healthtech g...
Boston Scientific announces recall of ENROUTE Transcarotid NPS
The FDA is aware that Boston Scientific (BSX) has issued a letter to affected customers recommending certain Percutaneous Catheter be removed from where they are used or sold. Devices may…
Boston Scientific Stock Is Falling as Cyberattack Puts More Strain on the Medical Device Maker
Boston Scientific stock falls as the medical device maker announces the latest batch of bad news for the company.
Morning Movers: Boston Scientific drops following cybersecurity incident
Stock futures are little changed as investors largely sit on the sidelines ahead of Nvidia’s earnings after the close. Investors are looking for evidence that the enormous AI infrastructure spending…
Medical device maker Boston Scientific is being hit by a cyber attack. The shares are falling
Boston Scientific was hit with a cyberattack that is affecting its operations, the company said Wednesday in an SEC filing. The attack is continuing to disrupt the company's ability to ship products, ...
Boston Scientific hit by cyberattack, global operations affected
Boston Scientific said on Wednesday that a cybersecurity incident had disrupted global operations, including some information systems used to process and ship customer orders.
Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
MARLBOROUGH, Mass., Aug. 10, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 21st Annual Healthcare Conference on Thursday, September 10, 2026.
Penumbra, Inc. Reports Second Quarter 2026 Financial Results
ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.